Galenica Reports Robust Sales Growth in Third Quarter

Galenica AG has announced a continued increase in sales for the third quarter of 2024. The company achieved net sales of CHF 2,864.8 million, marking a growth of 4.1%, surpassing the overall pharmaceutical market in Switzerland which grew by 2.9%. The sales boost was attributed to a strong demand for generics and biosimilars, alongside an increase in cold-related healthcare needs.

The Products & Care segment saw a rise in net sales by 4.0% to CHF 1,242.6 million. Retail (B2C) sales experienced a modest growth of 3.8%, with local pharmacies contributing significantly. However, "Pharmacies at Home" registered a slight decline of 1.4%. In the Professionals (B2B) sector, sales grew by 5.8%, driven by strong performances in both Products & Brands and Services for Professionals.

The Logistics & IT segment reported an increase of 4.5% in net sales, with the Wholesale area and Logistics & IT Services both contributing positively to the overall performance.